A Phase II Trial of Mutation-Targeted Therapy With Sunitinib or Everolimus in Patients With Advanced Low-or Intermediate Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery
Phase of Trial: Phase II
Latest Information Update: 31 Jul 2018
At a glance
- Drugs Everolimus (Primary) ; Sunitinib (Primary)
- Indications Gastrointestinal cancer; Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- 24 Jul 2018 Planned End Date changed from 6 Sep 2021 to 31 Dec 2025.
- 24 Jul 2018 Planned primary completion date changed from 7 Sep 2020 to 31 Dec 2024.
- 10 Jun 2017 Biomarkers information updated